Floatz logo

dn-101

Adenocarcinoma

Rockefeller UniversitySmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Adenocarcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 4BBB
Carboplatin
Blueprint Medicines Corporation
Phase 4BBB
Irinotecan
University of Chicago
Phase 2BBB
(+)-VINCRISTINE
Abramson Cancer Center at Penn Medicine
Phase 2BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

dn-101 is also rated in:

Friedreich AtaxiaDormant
B
Indicative ·
62 / 100
View asset →
PsoriasisDormant
B
Indicative ·
59 / 100
View asset →
Facial AngiofibromaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →